Blueprint Medicines(BPMC) Prnewswire·2025-04-25 12:00Company Overview - Blueprint Medicines Corporation is a global, fully integrated biopharmaceutical company focused on inventing life-changing medicines [3] - The company aims to alleviate human suffering by addressing important medical problems in two core areas: allergy/inflammation and oncology/hematology [3] - Blueprint Medicines has a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) for systemic mastocytosis (SM) in the U.S. and Europe [3] Upcoming Events - The company will host a live conference call and webcast on May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and provide a corporate update [1] - Access to the live conference call can be obtained by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 082088 [2] - An archived webcast will be available on the company's website approximately two hours after the call and will remain accessible for 30 days [2] Research and Development Focus - Blueprint Medicines is advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases, including SM and chronic urticaria, as well as breast cancer and other solid tumors [3]